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Background: Cytomegalovirus (CMV) infection is now the commonest congenital form of infective neurological
handicap, recognized by the Institute of Medicine as the leading priority for the developed world in congenital
infection. In the absence of an effective vaccine, universal screening for CMV in pregnancy has been proposed, in
order that primary infection could be diagnosed and- potentially- the burden of disability due to congenital CMV
prevented.
Discussion: Universal screening for CMV to identify seronegative women at the beginning of pregnancy could
potentially reduce the burden of congenital CMV in one of three ways. The risk of acquiring the infection during
pregnancy has been shown to be reduced by institution of simple hygiene measures (primary prevention). Among
women who seroconvert during pregnancy, CMV hyperimmune globulin (CMV HIG) shows promise in reducing the
risk of perinatal transmission (secondary prevention), and CMV HIG and/ or antivirals may be effective in reducing
the risk of clinical sequelae among those known to be infected (tertiary prevention). The reports from these studies
have re-ignited interest in universal screening for CMV, but against the potential benefit of these exciting therapies
needs to be weighed the challenges associated with the implementation of any universal screening in pregnancy.
These include; the optimal test, and timing of screening, to maximize detection; an approach to the management
of equivocal results, and the cost effectiveness of the proposed screening program. In this article, we provide an
overview of current knowledge and ongoing trials in the prevention, diagnosis and management of congenital
CMV. Recognising that CMV screening is already being offered to many patients on an ad hoc basis, we also
provide a management algorithm to guide clinicians and assist in counseling patients.
Summary: We suggest that- on the basis of current data- the criteria necessary to recommend universal screening
for CMV are not yet met, but this position is likely to change if trials currently underway confirm that CMV HIG and/
or antivirals are effective in reducing the burden of congenital CMV disease.Background
Cytomegalovirus (CMV) infection remains the commonest
cause of infective neurological handicap since implementa-
tion of universal rubella vaccination. The number of chil-
dren affected by congenital CMV is similar to other
conditions such as Down Syndrome, for which routine
screening is advocated and community awareness is high
[1]. The birth prevalence of congenital CMV is estimated
at 0.64% and 11% of these infants are symptomatic [2].
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reproduction in any medium, provided the or10,000 affected infants, not dissimilar to conditions for
which screening is currently recommended, such as early
onset groups B streptococcus infection, with a prevalence
of 4.3/10,000 [3] and Down syndrome with a birth preva-
lence of 11/10,000 births [4]. CMV infected infants who
are symptomatic at birth have a 5-10% neonatal mortality
rate and, among survivors, sequelae may be severe and life-
long [5]. CMV may also be an important contributor to
antenatal stillbirth [6]. Accordingly, the Institute of Medi-
cine has identified development of a CMV vaccine as the
highest priority in congenital infectious diseases in the de-
veloped world but, while results from a recent phase 2
vaccine trial are encouraging [7], there is no effective vac-
cination imminent.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In an attempt to reduce the disease burden of congenital
CMV, some clinicians and patient groups have advocated
for CMV screening in pregnancy in order that primary
infection- that associated with the highest risk of both peri-
natal transmission and clinical consequences- can be diag-
nosed and, potentially, congenital CMV and its sequelae
prevented. Screening for CMV could take one of several
forms. The first approach would be universal screening of
all women prior to, or in early pregnancy, to (i) identify
seropositive women who could be reassured that they are
not at risk of primary CMV in pregnancy, and (ii) identify
seronegative women who can be given advice to minimize
CMV acquisition in pregnancy. Such women may be of-
fered serial serology during pregnancy, to look for evidence
of serconversion. The second approach is to only screen
women at increased risk. The highest risk group comprises
women with frequent or prolonged contact with children
under the age of three; women with young children at
home or those that work in a day care setting. A third ap-
proach is to perform ‘once off ’ serology, including avidity
testing at around 20 weeks in order to identify most pri-
mary infections that have occurred early in pregnancy (the
time of greatest risk). The final screening approach is that
most aligned with current clinical practice; targeted assess-
ment on the midtrimester morphology ultrasound for fea-
tures of congenital CMV (such as ventriculomegaly,
intracerebral calcifications, microcephaly, echogenic bowel,
midtrimester intra-uterine growth restriction), and second-
ary maternal serology screening if positive features are iden-
tified. Each method has obvious benefits and limitations.
Cahill et al have performed a cost-effectiveness analysis,
modeling the latter three strategies, and concluded that
universal screening is the most cost-effective approach, as-
suming an efficacious treatment in the form of CMV hyper-
immune globulin (discussed below) was available [8].
Nevertheless, the proposed ‘once off serology’ has some
limitations; seronegative women are unable to be advised
on strategies to minimize CMV acquisition in early preg-
nancy; some women will have been exposed but not yet
seroconverted at the time of serology; some women who
have had periconceptual or early pregnancy infection may
have avidity above the threshold; and the opportunity to re-
duce fetal infection with treatment in pregnancy may have
been lost. It is for these reasons that several countries have
adopted early or pre pregnancy screening, followed by serial
follow up serology of seronegative women in order to de-
tect seroconversion. The remainder of this article addresses
how such an approach might work in clinical practice.
Potential interventions:
Our advancing knowledge of CMV means that many of the
Wilson and Junger criteria commonly applied to screening
tests [9] are now met for CMV; CMV is an importantcondition, diagnostic testing is available and the natural his-
tory of the condition is known. Nevertheless, universal
screening for CMV would be predicated on the assumption
that a safe, cost effective and accepted treatment or inter-
vention exists to reduce the risk of congenital CMV among
women found to be seronegative. Universal screening in
pregnancy is offered for conditions of even lower preva-
lence such as Rubella [10], Hepatitis B [11] and syphilis
[12] because of the opportunity to reduce congenital infec-
tion with simple, safe and effective interventions such as
post partum rubella vaccination, post exposure prophylaxis
for Hepatitis B, and timely treatment of maternal syphilis
with penicillin. Interventions to reduce the risk of congeni-
tal CMV among seronegative women may be one of three
types; primary prevention (preventing maternal seroconver-
sion during pregnancy), secondary prevention (preventing
fetal transmission following maternal seroconversion) or
tertiary prevention (preventing disease sequelae among
infected fetuses). Many of the knowledge gaps surrounding
such interventions are beginning to close, re-igniting the
screening debate. In part this is because several countries,
including Israel and some European centres, have been
conducting population based studies incorporating univer-
sal screening for some time. From such studies has come
valuable information on CMV epidemiology [13,14], reli-
ability of serological screening [15], key biological mecha-
nisms for placental and fetal damage [16] and the potential
efficacy of prevention strategies [17] and fetal treatment
[18]. These findings highlight the value of screening studies
not just to the individual, but to the broader medical com-
munity, providing the necessary data to inform future
screening policy.
In this article we provide a review of these and other
studies, summarizing current knowledge and ongoing tri-
als in the prevention, diagnosis and management of con-
genital CMV. Recognising that many clinicians have
already commenced screening using one or more of the
proposed screening strategies, we present the evidence in
a temporal clinical sequence; (i) the management of sero-
negative women; (ii) the management following maternal
seroconversion and (iii) the management of pregnancies
where the fetus is known to be infected, summarized in
Figures 1 and 2.
Discussion
Management of seronegative women
Whilst it is recognized that infants can have congenital
CMV as a result of maternal CMV re-infection or reactiva-
tion during pregnancy [19] (so called non primary infec-
tions), the risk of perinatal transmission [2] and subsequent
sequelae involving long-term disability [5] is much higher
among primary than non-primary infections. Accordingly,
prevention of primary CMV during pregnancy is recog-
nized as being of the greatest importance. Among women,
Figure 1 Proposed algorithm for CMV screening.
Figure 2 Proposed algortithm for management of women with IgG positive/IgM positive results at the time of screening.
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34 years to 79% between the ages of 35-39 years, which is
consistent with other studies suggesting approximately 50%
of pregnant women are CMV non-immune. Of these, 1-2%
will undergo seroconversion during pregnancy [19]. High-
risk populations for seroconversion include day care
workers (8% seroconversion per annum), and parents of
children shedding CMV (24% seroconversion per annum)
[20]. Seroconversion may be silent as CMV infection in im-
munocompetent adults is commonly asymptomatic, al-
though a retrospective history of symptoms (flu like
symptoms, fever, myalgia) and accompanying laboratory
features (lymphocytosis, elevated amino transferase) was
reported in over 50% of pregnant women with primary
CMV in one study [21]. Universal screening for seroconver-
sion is nevertheless the most reliable means of identifying
primary infection in pregnancy.
Hygiene advice to seronegative women
One of the benefits of universal screening is that sero-
negative women can be identified and advised how to
minimise the risk of seroconversion during pregnancy. A
summary of the measures recommended by the Centres
for Disease Control and Prevention are presented below
[22].
 Wash hands with soap and water for 15-20 seconds
after handling body fluids, dirty laundry or children’s
toys, changing nappies, bathing or feeding young
children
 Do not share food, drinks or eating utensils with
young children; do not put a dummy in your mouth
or share a toothbrush with a young child
 Avoid contact with saliva when kissing a child
 Clean toys, countertops etc that come into contact
with children’s urine or saliva
Such measures have been proven to be effective. A
French study reported on over 2,500 CMV seronegative
women at 12 weeks gestation. Institution of simple hy-
giene measures such as regular hand washing, and
avoiding intimate contact with children under the age of
6 years, resulted in rate of serocoversion prior to 36
weeks gestation of only 0.2% among these women [17].
In a related study, this group reported that CMV screen-
ing was received favourably when offered to women at
12 weeks’ gestation [23]. In this study, 3792 women
known to be non-immune, or with unknown immune
status, were advised of the potential consequences of
primary CMV, were given hygiene advice to minimise
CMV acquisition, and were advised regarding the pau-
city of scientific data on the value of screening. Despite
this, 96.7% of women accepted serological screening,
suggesting that the uptake of CMV screening whenwomen are informed of the importance of CMV infec-
tion, is likely to be high.
Diagnosis of primary infection
Seroconversion can be reliably diagnosed when a previ-
ously seronegative woman develops CMV-specific IgG
and IgM antibodies. In the absence of previous serology,
CMV primary infection may be suspected in the presence
of IgM and low avidity IgG. CMV IgM positivity does not
always reflect recent infection and may be either a false
positive (related to intercurrent viral infection or presence
of auto-immune disease) or be a prolonged IgM response
(IgM seropositivity may persist for months to years). In
this scenario, IgG avidity may help to distinguish recent
from remote infection. Avidity refers to the strength of
binding of an antibody to the viral epitope, reflecting the
maturity of the antibody response. While the cut-off for
high avidity will vary according to the assay used, and
there are variations in results between assays, the presence
of a high avidity IgG generally infers that primary infection
occurred ≥12-16 weeks previously [15]. Expert interpret-
ation of serology in the setting of a CMV IgM positive re-
sult is important to ascertain whether this is as a result of
a primary, non primary or past infection. Given the lower
incidence of transmission and sequelae, confirmation of
past or non primary infection will provide reassurance to
many women, evidenced by the reduced incidence of inva-
sive testing and termination of pregnancy in this group
[24]. If primary infection is confirmed, it is important that
expert advice is sought from a maternal fetal medicine
and/or infectious diseases specialist to provide advice on
diagnosing fetal infection, predicting infant sequelae and
the emerging role of in utero therapy.
Management following maternal seroconversion
Diagnosing fetal infection
The risk of fetal infection following primary maternal sero-
conversion is estimated at 32.3% overall, much higher than
the risk associated with non primary infection (1.4%) [2].
The risk of fetal infection is gestation dependent; a recent
series of 248 cases of primary CMV confirmed a fetal
transmission rate of 17% when maternal infection occurred
preconceptually (from 1-10 weeks prior to last missed
period), 35% when infection occurred periconceptually (de-
fined as 1 week prior to 5 weeks post missed period), and
30%, 38% and 72% for the remainder of the first trimester
and second and third trimesters, respectively [14]. These
transmission rates are remarkably similar to those reported
in a Belgian study in 2010, the largest study to date.
Among 524 seroconversions, the mean rate of transmission
was 47%, rising from 35% where seroconversion occurred
in the first trimester to 44% and 73% when seroconversion
occurred during the second and third trimester, respect-
ively [13].
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In order to allow sufficient time for placental transmission,
renal infection and tubular excretion, establishment of ad-
equate diuresis and excretion of CMV into the fetal urine,
amniocentesis has maximal sensitivity if performed 7 weeks
after maternal seroconversion and should be performed
after 20 weeks gestation, whichever is later [25]. A positive
result for CMV using PCR on the amniotic fluid confirms
fetal infection (100% positive predictive value), but is
not predictive of long-term sequelae. The negative pre-
dictive value of amniocentesis for fetal infection is ap-
proximately 95% [26]. In a series of 10 congenitally
infected infants whose amniocenteses were negative at
21 weeks (performed at least 7 weeks after presumed
maternal infection), four had CMV-related morbidity
diagnosed at follow up (sensorineural hearing loss), two
of whom responded to antiviral treatment [27]. This un-
derscores the importance of newborn screening by way
of a neonatal urine in the first three weeks of life for all
children born to women who have seroconverted in
pregnancy, including those with a negative PCR on
amniocentesis.
Can fetal infection be prevented?
In 2005, a non-randomised study reported a reduction in
vertical transmission from 40% (19/47) to 16% (6/37)
among women with CMV seroconversion in pregnancy
following maternal administration of CMV hyperimmune
globulin (CMV HIG) [18]. Intravenous immunoglobulin
(IVIG) was first used in the 1950s, and is a concen-
trated plasma product containing at least 90% intact
IgG, generated from a pool of screened plasma donors.
IVIG has a favourable safety profile in pregnancy, with
adverse reactions occurring in less than 5% of patients.
IVIG has been safely used for immunomodulation in
pregnancy for conditions such as autoimmune and
allo-immune thrombocytopenia and severe red blood
cell iso-immunisation since the 1980s [28]. CMV HIG
is collected only from donors with high levels of CMV
IgG. The reduction in fetal transmission among women
with primary CMV in pregnancy is presumed attribut-
able to the high IgG avidity in the CMV HIG, which
has both neutralising and immunomodulating activity.
Buxman et al have also reported lower than expected
rates of CMV transmission (23%) following administra-
tion of CMV HIG to women with a periconceptual, first
or second trimester diagnosis of primary CMV [29].
The data from these two small studies are encour-
aging, and three large randomised controlled trials have
commenced examining the utility of administering CMV
HIG to pregnant women who have seroconverted during
pregnancy to prevent fetal infection [30,31]. The efficacy
study of Human CMV (HCMV) hyperimmune globulin
to prevent congenital HCMV infection (CHIP) trial hascompleted and preliminary results have been presented
[32]. In summary, the trial included 122 women with
primary CMV confirmed between 5 and 26 weeks gesta-
tion, where randomisation and treatment were required
within 6 weeks of the presumed onset of maternal infec-
tion. The trial was powered to show the same magnitude
of reduction in transmission with CMV HIG administra-
tion as was seen in the original Nigro trial (ie from 40%
to 16%) [18]. This trial reported a trend toward reduced
transmission among those administered CMV HIG,
from 44% to 32%, although this result failed to achieve
statistical significance. The remaining two prevention
trials, one based in Europe [31] and the other based in
the United States are yet to complete recruitment.
Based on the currently available evidence, the two studies
to date- if combined – would suggest an approximate re-
duction in fetal transmission of 50% with timely adminis-
tration of CMV HIG following maternal seroconversion,
but results of the ongoing trials will be able to estimate this
effect with greater precision, and will be critical in deter-
mining the place of CMV screening in pregnancy. These
prevention trials will also be crucial in determining the op-
timal rescreening interval of seronegative women during
pregnancy. If administration of CMV HIG is confirmed to
significantly reduce the incidence of fetal infection follow-
ing maternal seroconversion, then repeat serological testing
at frequent intervals during pregnancy would be indicated
to optimise timely detection of primary CMV, and enable
prompt institution of treatment. Monthly rescreening has
been has been reported in some series [18], which may op-
timise detection of maternal seroconversion and reduce
the risk of fetal infection prior to CMV HIG administra-
tion, but the feasibility and cost effectiveness of such an ap-
proach on a large scale remains to be determined.
Management of pregnancies where the fetus is known to
be infected
The risk of fetal sequelae
Clinical sequelae resulting from CMV infection may result
from placental and/or fetal infection. Histological changes
associated with placental CMV infection include avascular
and hydropic villi, fibrinoid deposits and syncytial knotting
[16], all of which may impair transport of oxygen and nutri-
tion to the developing fetus. Clinical sequelae from placen-
tal infection may include intra-uterine growth restriction,
hepatosplenomegaly and stillbirth. Sequelae such as central
nervous system damage and sensori-neural hearing loss re-
sult more directly from fetal cytopathic injury, although
modulation of placental immune function may also play a
role in mediating fetal injury [33]. The risk of long term
complications is inversely related to gestational age, with
the highest rate of severe sequelae associated with infection
in the first trimester. Neurological sequelae (including hear-
ing loss) have been reported in approximately 30% of
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diagnosed in the first trimester, which is more than twice
the rate of sequelae following later infection [34]. Overall,
10-15% of congenitally infected infants will have symptoms
at birth, including jaundice, hepatosplenomegaly, hydrops,
thrombocytopenia, anaemia, microcephaly, seizures and
chorioretinitis. Among these infants, perinatal mortality
may be as high as 10%, and the risk of long-term neuro-
logical sequelae among survivors lies between 40% and 60%
[5]. Of the remaining 90% of infants that are asymptomatic
at birth, approximately 10-15% will develop symptoms later,
most commonly sensorineural hearing loss [5].
Predicting symptomatic infants
In ongoing pregnancies where fetal infection has been con-
firmed on amniotic fluid, ultrasound surveillance is
recommended for evolving features of CMV-related fetal
damage, including the development of intra-uterine growth
restriction, and oligo- or polyhydramnios. System specific
features include the presence of echogenic bowel, intra-
hepatic calcifications (intra-hepatic echodensities with
brightness equivalent to bone and with posterior acoustic
shadowing [35]), pleural effusions, ascites or generalised
hydrops. The optimal frequency of ultrasound surveillance
is unknown, but ultrasound examinations are generally
performed every 2-4 weeks following confirmation of fetal
infection.
Optimal evaluation of the central nervous system
(CNS) with ultrasound involves targeted, serial ultra-
sound examination, often employing the transvaginal,
approach to optimise CNS views. CNS findings associ-
ated with congenital CMV include ventriculomegaly, the
presence of intra-ventricular adhesions, periventricular
calcifications and cysts, cortical or cerebellar abnormal-
ities and the presence of haemorrhage. Many studies
have reported that ultrasound identifies only a minority
of fetuses who will subsequently be found to be symp-
tomatic at birth [36], but Farkas et al have recently
reported in a small study that congenitally infected chil-
dren with normal imaging showed no difference in cog-
nitive, language or motor development when compared
to gestation-matched controls at a median follow up of
34 months [37]. This small study suggests that, to opti-
mise sensitivity, follow up examinations of congenitally-
infected fetuses should be performed by those with
expertise in obstetric neurosonography.
The role of fetal MRI is evolving in the evaluation of de-
velopmental or acquired brain lesions, with MRI providing
superior assessment of the cerebral cortex and white mat-
ter. Among fetuses with confirmed CMV infection, the use
of MRI in addition to ultrasound improves the positive pre-
dictive value for brain lesions confirmed on postnatal
examination from 71% with ultrasound alone to 89% [37].
The sensitivity of fetal MRI increases with advancinggestation, although the upper gestational limit may be
influenced by pragmatic considerations such as availability
of in utero treatment and access to late termination of preg-
nancy in the event that significant abnormalities are
confirmed.
Where significant CNS changes are observed on ultra-
sound (ventriculomegaly, microcephaly, cerebellar hypo-
plasia), it is highly likely that these will be associated with
significant sequelae. Benoist et al has reported that a
‘symptomatic ultrasound’ was associated with an 85-90%
risk of brain abnormalities being confirmed at post
mortem (following termination of pregnancy) or postnatal
ultrasound examination [38]. Recent studies suggest that
the combination of expert neurosonography and MRI im-
proves the detection of CNS abnormalities among CMV-
infected fetuses, and that normal examinations provide
some reassurance [39,40]. Nevertheless, not all sequelae
are detectable with antenatal imaging, the most obvious
being sensorineural hearing loss, and the limitations of
imaging in predicting outcome need to be addressed dur-
ing counselling.
Can in utero treatment reduce the risk of sequelae among
infected infants?
In the past, the only effective means of preventing dis-
ability due to congenital CMV was to offer termination
of pregnancy upon the antenatal diagnosis of definite or
possible sequelae. The difficulties of this approach are
compounded by the fact that by the time consequences
of infection have become apparent on imaging, access to
termination of pregnancy may be uncertain, with varying
legislation on acceptable indications for, and upper ges-
tational limit of, termination of pregnancy. Alternate
management of the affected fetus includes in utero ther-
apy with CMV HIG or antivirals, with recent studies
reporting encouraging results [18,41].
One non-randomised clinical trial in 2005 suggested that
CMV HIG may be efficacious in treating congenital CMV
in utero, with reduced sequelae reported at 2 year follow up
[18]. This encouraging early data has been followed by two
further studies, both confirming fetal benefit with adminis-
tration of CMV HIG following confirmation of fetal infec-
tion. Visentin et al in a non randomised study reported on
the 12 month follow up of 68 infants confirmed to have
fetal infection during pregnancy. Poor outcome at 12
months (defined as audiological or neurological abnormal-
ity, presence of necrotizing enterocolitis or chronic liver
disease) was found in 16 of 37 untreated women (43%)
compared to 4 of 31 (13%) of women treated with a single
dose of CMV HIG between 20 and 24 weeks following the
diagnosis of fetal infection (P < .01) [41]. In a recent case
control study, Nigro et al confirmed that the only signifi-
cant risk factor for having a symptomatic infant at 1-5 years
of age following the diagnosis of congenital CMV at less
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ceived CMV HIG [42]. Such benefits are presumed due to
both the high avidity and neutralizing activity of CMV
HIG, and/or down-regulation of immune-mediated fetal
and placental damage [16]. Administration of standard
intravenous immunoglobulins (IVIG), obtained from an un-
selected donor pool, has also been demonstrated to in-
crease CMV IgG and avidity among women with primary
infection in pregnancy. If future studies demonstrate com-
parable efficacy, this may be able to reduce the cost and im-
prove access to such therapy [43]. There are no ongoing
trials specifically examining the role of CMV HIG for treat-
ment of symptomatic disease in infected fetuses, and ad-
ministration of CMV HIG to women known to have an
infected fetus is becoming standard practice. Further data
on the value of treatment is only likely to come from pro-
spective registries comparing the outcomes of CMV HIG
treated, versus untreated, pregnancies.
A single trial has evaluated the role of administering
oral valacyclovir to women carrying a fetus with con-
firmed CMV infection. Although this trial demonstrated a
significant reduction in fetal viremia post treatment with
valacycolvir, the outcome among treated infants was no dif-
ferent to an untreated historical control group [44]. A
double blind randomised controlled trial is currently under-
way to evaluate the role of valacyclovir in women whose fe-
tuses demonstrate extracerebral manifestations of CMV
infection; completion of this trial is expected in 2013.
Summary
Congenital CMV is the commonest infective cause of
neurological handicap and is a significant contributor to
long term disability. Congenital CMV is common and
important enough to justify its place among other rou-
tine antenatal screening tests. The case for CMV screen-
ing in pregnancy is supported by the proven reduction
in maternal primary infection following institution of
simple hygiene measures (primary prevention). On the
other hand, further data is awaited from randomized tri-
als currently underway to better estimate the reduction
in fetal infection achieved with CMV HIG among re-
cently seroconverted women (secondary prevention). In
utero treatment with CMV HIG appears to reduce clin-
ical sequelae among fetuses confirmed to be infected
(tertiary prevention), and CMV HIG is currently being
offered to women with a known infected fetus identified
through current screening strategies. An ongoing trial
will soon clarify the role of antivirals such as valacyclovir
to reduce sequelae in symptomatic fetuses.
The results of these ongoing trials will inform the
current clinical algorithm for diagnosis and manage-
ment of maternal and fetal CMV infection in order that
diagnostic tests and therapies may be appropriately
targeted, and cost effectiveness of screening models canbe established. Whether universal serological screening
should be implemented for the detection of primary
CMV in pregnancy in 2013 may be neither ‘yes’ nor
‘no’, but ‘not yet’, recognizing that this position may
soon change if trials currently underway confirm that
intervention in pregnancy can reduce the risk of fetal
infection and, in turn, the considerable burden of death
and survival with disability due to congenital CMV.
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